Lupin informs about settlement and license agreement

10 Feb 2026 Evaluate

Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations and further to its earlier intimation dated April 16, 2025, in respect of a patent infringement dispute with Astellas Pharma, Inc., Astellas Ireland Co., and Astellas Pharma Global Development, Inc. (collectively ‘Astellas’) in relation to its product ‘Mirabegron’, Lupin has informed that the Company and its wholly owned subsidiary Lupin Pharmaceuticals, Inc., USA, have entered into a Settlement and License Agreement (‘Agreement’) with Astellas. Under the terms of the Agreement, Lupin will pay Astellas (1) USD 90 million, which includes a Prepaid Option Payment of USD 75 million, and (2) a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September 2027. The settlement terms are confidential. This settlement resolves Lupin’s pending litigation with Astellas and allows Lupin to continue to sell its Mirabegron product.

The above information is a part of company’s filings submitted to BSE. 

Lupin Share Price

2340.75 39.05 (1.70%)
10-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1813.00
Dr. Reddys Lab 1313.90
Cipla 1333.10
Zydus Lifesciences 922.90
Lupin 2340.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×